



저작자표시-비영리-변경금지 2.0 대한민국

이용자는 아래의 조건을 따르는 경우에 한하여 자유롭게

- 이 저작물을 복제, 배포, 전송, 전시, 공연 및 방송할 수 있습니다.

다음과 같은 조건을 따라야 합니다:



저작자표시. 귀하는 원저작자를 표시하여야 합니다.



비영리. 귀하는 이 저작물을 영리 목적으로 이용할 수 없습니다.



변경금지. 귀하는 이 저작물을 개작, 변형 또는 가공할 수 없습니다.

- 귀하는, 이 저작물의 재이용이나 배포의 경우, 이 저작물에 적용된 이용허락조건을 명확하게 나타내어야 합니다.
- 저작권자로부터 별도의 허가를 받으면 이러한 조건들은 적용되지 않습니다.

저작권법에 따른 이용자의 권리는 위의 내용에 의하여 영향을 받지 않습니다.

이것은 [이용허락규약\(Legal Code\)](#)을 이해하기 쉽게 요약한 것입니다.

[Disclaimer](#)

의학석사 학위논문

**The effect of ascorbic acid deficiency
on bone formation
in *Gulo* knock out mice**

Gulo 유전자 적중 생쥐에서의
아스코르빈산 결핍이
골형성에 미치는 영향

2012년 8월

서울대학교 대학원
의학과 해부학 전공
김 원

A thesis of the Master's degree

Gulo 유전자 적중 생쥐에서의
아스코르빈산 결핍이
골형성에 미치는 영향

**The effect of ascorbic acid deficiency
on bone formation
in *Gulo* knock out mice**

August 2012

Department of Anatomy,
Seoul National University College of Medicine
Won Kim

Gulo 유전자 적중 생쥐에서의
아스코르빈산 결핍이
골형성에 미치는 영향

지도교수 이 왕 재

이 논문을 의학석사학위논문으로 제출함.

2012년 4월

서울대학교 대학원

의학과 해부학 전공

김 원

김원의 의학석사학위논문을 인준함.

2012년 7월

위 원 장 _____ (인)

부위원장 _____ (인)

위 원 _____ (인)

**The effect of ascorbic acid deficiency
on bone formation
in *Gulo* knock out mice**

**by
Won Kim**

(Directed by Wang Jae Lee, MD, PhD)

**A thesis submitted to Department of Anatomy
in partial fulfillment of the requirement
of the Degree of Master of Science in Anatomy
at Seoul National University College of Medicine**

July 2012

Approved by Thesis Committee:

Professor _____ Chairman

Professor _____ Vice chairman

Professor _____

ABSTRACT

L-gulonolactone oxidase (Gulo) is an essential enzyme in the synthesis of ascorbic acid from glucose. It is known that gulo is mutated in humans and certain primates. Gulo (-/-) mice are a useful animal model of human scurvy when they are raised under an ascorbic acid-deficient condition, since Gulo (-/-) mice have a defect in the expression of the gulo gene. Based on previous findings on bone abnormalities, including multiple chondrocostal junction fractures in Gulo (-/-) mice upon ascorbic acid insufficiency, the specific factors at work are investigated on the present study. At 4 weeks after ascorbic acid withdrawal, a definite loss of weight was found in ascorbic acid-insufficient Gulo (-/-) mice. Interestingly, the plasma level of osteocalcin, which is secreted solely by osteoblasts and is thought to play a role in the metabolic regulation of bone, was dramatically decreased in ascorbic acid-insufficient Gulo (-/-) mice 3 weeks after ascorbic acid withdrawal. In addition, it was no longer detected at 4 weeks after ascorbic acid withdrawal. The tibia weight of the ascorbic acid-sufficient Gulo (-/-) mice was significantly higher than the other three groups. The trabecular bone volume was decreased near the growth plate. Moreover, we found a significant decrease in the trabecular bone attachment to the growth plate in ascorbic acid-insufficient Gulo (-/-) mice at 3 or 4 weeks after ascorbic acid withdrawal. Taken together, there are severe defects in normal bone formation as the result of ascorbic acid insufficiency, and this effect is closely related to a decrease in the osteocalcin level.

Keywords: ascorbic acid, vitamin C, Gulo, osteocalcin, bone formation

Student number: 2007-23330

CONTENTS

Abstract	i
Contents	iii
List of Figures	iv
List of Abbreviations	v
Introduction	1
Material and Methods	3
Results	6
Discussion	15
Reference	20
Abstract in Korean	25

LIST OF FIGURES

Figure 1. The weights of mice at baseline and after ascorbic acid withdrawal	7
Figure 2. The plasma levels of calcium and phosphorus after ascorbic acid withdrawal	9
Figure 3. The plasma levels of alkaline phosphatase and osteocalcin after ascorbic acid withdrawal	10
Figure 4. Tibia dry weight and the ratio of tibia weight per final body weight at the end of experiment	12
Figure 5. Proximal metaphysis and growth plate of proximal tibia after ascorbic acid withdrawal	14

LIST OF ABBREVIATIONS

3w *Gulo* (-/-) : 3 week ascorbic acid-insufficient *Gulo* (-/-) mice

4w *Gulo* (-/-) : 4 week ascorbic acid-insufficient *Gulo* (-/-) mice

ALP: alkaline phosphatase

AsA: ascorbic acid

BMD: bone mineral density

Gulo: L-gulonolactone oxidase

Gulo (-/-) + AsA: ascorbic acid-sufficient *Gulo* (-/-) mice

H&E: hematoxylin and eosin

HDL: high density lipoprotein

LDL: low density lipoprotein

mRNA: messenger ribonucleic acid

ODS rat: osteogenic disorder shionogi rat

rER: rough endoplasmic reticulum

SD: standard deviation

ND: not detected

WT: wild type

INTRODUCTION

Scurvy is associated with certain connective tissue symptoms, such as vascular purpura, bleeding and gum abnormalities (1). It is caused by severe ascorbic acid-deficiency, because ascorbic acid is essential for the normal synthesis of collagen (2). When it is considered that the organic bone matrix is mainly composed of Type I collagen (3), ascorbic acid-deficiency might have a role in bone abnormalities. An inhibition of new bone formation after bone grafting and a delay in bone regeneration after injury have been observed in scorbutic guinea pigs (4, 5). In human beings, ascorbic acid-deficiency also causes bone abnormalities such as microfracture, osteolysis and osteoporosis (6-8). However, not only deficiency, but also supplementation with mega-dose ascorbic acid might exert an effect on bone. Indeed, epidemiologic studies were recently reported that suggested a supplementation with ascorbic acid may enhance bone formation and overall bone health (9, 10).

Since ascorbic acid is synthesized from glucose in most animals, they do not have to take in ascorbic acid by food. However, human beings cannot synthesize ascorbic acid (11). This defect is due to the lack of L-gulonolactone oxidase that is an essential enzyme for the synthesis of ascorbic acid that converts L-gulonolactone to L-ascorbic acid (12, 13). Therefore, ascorbic acid must be obtained in food in humans. For this reason, it is believed that ascorbic acid is a clinically important nutrient. Most

experimental animals are able to synthesize large amounts of ascorbic acid by themselves. This is a major impediment to the study of the *in vivo* effect of ascorbic acid. Therefore, the *Gulo* (-/-) mice used in this experiment are considered a useful animal model for the investigation of the *in vivo* effect of ascorbic acid. Because these mice have a defect in the *gulo* gene, they are unable to synthesize ascorbic acid.

Gulo (-/-) mice were originally generated for a study of the effect of ascorbic acid on the prevention of atherosclerotic plaque formation upon ascorbic acid insufficiency (14). Therefore, *Gulo* (-/-) mice are a very useful model for studying the *in vivo* consequences of supplementation with ascorbic acid.

In the course of a previous investigation of the general characteristics of *Gulo* (-/-) mice (15), skeletal changes such as chondrocostal junction thickening and multiple fractures at 5 weeks after withdrawal of ascorbic acid were clearly evident. However, the specific mechanisms have remained largely undetermined. Therefore, we investigated the effect of ascorbic acid insufficiency on factors related to bone metabolism in *Gulo* (-/-) mice.

MATERIALS AND METHODS

Mice

Gulo (+/-) breeding pairs were obtained from the Mutant Mouse Regional Resource Center, MMRRRC (University of California, Davis, CA, USA). We determined the genotypes of the offspring by PCR as recommended in the literature (14). *Gulo* (-/-) and C57BL/6 wild type (WT) mice were maintained in specific pathogen free conditions in the animal facility at the Seoul National University College of Medicine. Twelve week old mice were used in this experiment and the protocol was reviewed and approved by Ethics Committee of the Seoul National University.

Supplementation and withdrawal of ascorbic acid

Gulo (-/-) mice were supplemented with ascorbic acid (3.3g/L, Sigma, St. Louis, MO, USA) in water to maintain the general health of the mice for 12 weeks. The mice were divided into three groups. One received continuous ascorbic acid supplementation until the end of the experiment, referred to as “ascorbic acid-sufficient *Gulo* (-/-) mice”. Another underwent a stoppage of ascorbic acid supplementation for the last 3 weeks of the experiment, referred to as “3 week ascorbic acid-insufficient *Gulo* (-/-) mice”. The last underwent a stoppage of ascorbic acid supplementation for the last 4 weeks of the experiment, referred to as “4 week ascorbic acid-insufficient

Gulo (-/-) mice”. To examine the general physiological changes in *Gulo (-/-)* mice upon ascorbic acid insufficiency, the body weight of each of the mice was measured at the beginning and end of the experiment.

Analysis of the biochemical components

At the end of the experiment, blood was collected from the intra-orbital plexus with a heparinized capillary tube. Plasma was obtained from each collected blood sample by centrifugation at 14,000 rpm for 30 min. The plasma levels of calcium, phosphorus and alkaline phosphatase (ALP) were measured with a chemistry analyzer (Hitachi 7070, HITACHI Science Systems, Ltd., Hitachinaka-shi, Japan). The plasma level of osteocalcin was measured with a mouse specific enzyme-linked immunosorbent assay (ELISA) kit following the manufacturer’s protocol (Biomedical Technologies, INC., Stoughton, MA, USA).

Determination of the tibia dry weight

Mice were sacrificed by cervical dislocation under ether anesthesia. The left was dissected and the surrounding soft tissues were removed. After de-fatting with a mixed solution of chloroform/ethanol (2:1) for 24 hours, the tibia was flushed out with saline to remove the remnant marrow element. The fat free tibia was then dried in an oven at 80°C over 48 hours. The tibia dry weight was measured with a microbalance (AEX-200G, SHIMADZU Corporation, Kyoto, Japan)

Histologic examination

The dissected right tibia was fixed in 4% paraformaldehyde for 24 hours after removal of the surrounding soft tissues. Decalcification was performed with 10% EDTA solution for 5 days. The fixed and decalcified tibia was embedded in paraffin and sectioned at 4 μm . Paraffin bone sections were stained with hematoxylin and eosin (H&E).

Statistical analysis

Results are presented as the mean \pm SD. Differences among the groups were tested using the Kruskal–Wallis test and the subsequent comparisons of each group were performed with the Mann-Whitney test. Data were analyzed using PASW for Windows (Version 18.0, SPSS Inc., Chicago, IL, USA). All the statistical outcomes were based on a two-sided test, and a P-value < 0.05 was regarded as statistically significant.

RESULTS

The weight of *Gulo(-/-)* mice was decreased 4 weeks after ascorbic acid withdrawal

To establish that all of the mice fit the same experimental conditions, we first determined the weight of each animal before starting the withdrawal of ascorbic acid. As shown in Figure 1A, there was no significant difference in body weight. The drinking water for the ascorbic acid-insufficient *Gulo (-/-)* mice was replaced with water that did not contain ascorbic acid. Interestingly, we did not find a significant change at 3 weeks after ascorbic acid withdrawal, but a definite change was observed at 4 weeks in the ascorbic acid-insufficient *Gulo (-/-)* mice. This suggests that ascorbic acid insufficiency does affect the loss of weight. However, it remains to be clarified whether it is accompanied by changes in bone formation and/or bone density.




Figure 1. The weight of mice at baseline (A) and after ascorbic acid withdrawal (B)

The weight of the mice was measured at baseline and after ascorbic acid withdrawal. The weight did not exhibit any significant difference among the groups at baseline (A). After ascorbic acid withdrawal in the *Gulo* (-/-) mice, the weight was significantly decreased at 4 weeks compared with that of the ascorbic acid-sufficient *Gulo* (-/-) mice (B). Data are presented as the means \pm SD, and each group included 5 animals. **p < 0.01.

The plasma levels of osteocalcin in *Gulo(-/-)* mice was decreased from 3 weeks after ascorbic acid withdrawal

To examine the effect of ascorbic acid insufficiency on bone metabolism, we measured the plasma levels of calcium, phosphorus, alkaline phosphatase and osteocalcin. At the end of the experiment, the plasma levels of calcium (Figure 2A) and phosphorus (Figure 2B) did not exhibit any significant difference among the groups. The plasma level of alkaline phosphatase, known as a non-specific marker of bone formation, was relatively higher in the ascorbic acid-sufficient *Gulo (-/-)* mice, but this was not statistically significant (Figure 3A). To examine the effect of ascorbic acid on bone formation more precisely, the plasma level of osteocalcin, which originates solely from bone, was measured. The plasma level of osteocalcin was significantly lower in the 3 week ascorbic acid-insufficient *Gulo (-/-)* mice than the WT and ascorbic acid-sufficient *Gulo (-/-)* mice (Figure 3B). In the 4-week ascorbic acid-insufficient *Gulo (-/-)* mice, osteocalcin was not detected in the plasma except in one mouse (7.8 ng/mL).




Figure 2. The plasma levels of calcium (A) and phosphorus (B) after ascorbic acid withdrawal

After ascorbic acid withdrawal in *Gulo* (-/-) mice for the last 3 or 4 weeks, the plasma levels of calcium (A) and phosphorus (B) were measured. The plasma levels of calcium and phosphorus did not exhibit any significant difference among the groups. The data are presented as the means \pm SD, and each group included 5 animals.




Figure 3. The plasma levels of alkaline phosphatase (A) and osteocalcin (B) after ascorbic acid withdrawal

After ascorbic acid withdrawal in *Gulo* (-/-) mice for 3 or 4 weeks, the plasma levels of alkaline phosphatase (A) and osteocalcin (B) were measured. The plasma level of alkaline phosphatase was not significantly different among the groups (A). The plasma level of osteocalcin was significantly lower in the 3-week ascorbic acid-insufficient *Gulo* (-/-) mice than those in the WT and ascorbic acid-sufficient *Gulo* (-/-) mice (B). In the 4-week ascorbic acid-insufficient *Gulo* (-/-) mice, osteocalcin was not detected in the plasma. Data are presented as the means \pm SD, ND = not detected, Each group included 5 animals. ** $p < 0.01$.

The tibia dry weight of the ascorbic acid-sufficient *Gulo (-/-)* mice was higher than in the other groups

To examine the total net effect of ascorbic acid-deficiency on bone metabolism during the experiment, tibia dry weight was measured after ascorbic acid withdrawal in the *Gulo (-/-)* mice for 3 or 4 weeks (Figure 4A). The tibia dry weight of the ascorbic acid-sufficient *Gulo (-/-)* mice was significantly higher than that in the other three groups. However, significant differences were not observed among the WT, 3-week and 4-week ascorbic acid-insufficient *Gulo (-/-)* mice. To adjust for the effect of general growth difference, the ratio of the tibia weight to final body weight was compared between the WT and ascorbic acid-sufficient *Gulo (-/-)* mice. The ratio was significantly higher in the ascorbic acid-sufficient *Gulo (-/-)* mice than the WT (Figure 4B).




Figure 4. Tibia dry weight and the ratio of the tibia weight to the final body weight at the end of the experiment

After ascorbic acid withdrawal in the *Gulo* (-/-) mice for the last 3 or 4 weeks, the tibia dry weight was measured (A). The tibia dry weight in the ascorbic acid-sufficient *Gulo* (-/-) mice was significantly higher than the other three groups. The ratio of the tibia weight to the final body weight was significantly higher in the ascorbic acid-sufficient *Gulo* (-/-) mice than the WT (B). Data are shown as the means \pm SD, Each group included 5 animals. * $p < 0.05$, ** $p < 0.01$.

The trabecular bone volume in the *Gulo (-/-)* mice was decreased near the growth plate starting at 3 weeks after ascorbic acid withdrawal

To examine the alteration in the bone architecture after ascorbic acid withdrawal, histologic examination was performed. The growth plate of the tibia was observed in all four groups, which shows that bony growth was not completed at that age (Figure 5). In the metaphysis, the trabecular bone was well organized in both the WT and ascorbic acid-sufficient *Gulo (-/-)* mice (Figure 5 A, B). In these two groups, trabecular bone was well attached to the growth plate (Figure 5 E, F). In the 3 and 4 week ascorbic acid-insufficient *Gulo (-/-)* mice, the trabecular bone volume was decreased near the growth plate (Figure 5 E, F), and there was a significant decrease in the trabecular bone attachment to the growth plate (Figure 5 G, H). These findings show that new bone formation was disturbed by ascorbic acid insufficiency.




Figure 5. The proximal metaphysis and growth plate of the proximal tibia after ascorbic acid withdrawal

After ascorbic acid withdrawal in *Gulo (-/-)* mice for 3 or 4 weeks, the mouse tibia was harvested, fixed, decalcified, sectioned at 4 μm and stained with H&E. Compared with the WT (A, E) and ascorbic acid-sufficient *Gulo (-/-)* mice (B, F), in the 3 week (C, G) and 4 week (D, H) ascorbic acid-insufficient *Gulo (-/-)* mice the trabecular bone volume was decreased near the growth plate, and there was a significant decrease in trabecular bone attachment to the growth plate.

DISCUSSION

It is well-known that ascorbic acid is a major co-factor for collagen synthesis. It is reported that various abnormalities in supporting tissues, such as scurvy and chondrocostal fracture, occur under a condition of ascorbic acid insufficiency (1, 16). The extensive physiological changes that occur in humans with ascorbic acid insufficiency are also reported in *Gulo (-/-)* mice. For example, decreased total cholesterol and high density lipoproteins (HDL), but increased low density lipoproteins (LDL) are found in both these mice and humans. A prominent decrease of catecholamine production is also reported. All of these developments are accompanied by a loss of weight (14). There are several reports on the role of ascorbic acid in the generation and maintenance of bone in animals under ascorbic acid-insufficient conditions. The osteogenic disorder shionogi (ODS) rat is unable to synthesize ascorbic acid due to the lack of L-gulonolactone oxidase, like humans and *Gulo (-/-)* mice. When ascorbic acid is insufficiently supplied to these rats, there is a detachment of osteoblasts, characterized by a round-shaped rough endoplasmic reticulum (rER), from bone surfaces due to the accumulation of malformed collagens inside the rER (17). In the bone of ascorbic acid insufficient guinea pigs, there was a remarkable reduction of hydroxyproline content and osteocalcin mRNA expression (18, 19). Moreover, decreases in the enzymatic activity of alkaline phosphatase in the bone and serum were also observed in ascorbic acid insufficient guinea pigs (19). It is generally known that spontaneous fracture occurs in sfx mice, because they cannot

synthesize ascorbic acid due to the deletion of the L-gulono- γ -lactone oxidase gene, the same as *Gulo* (-/-) mice. Interestingly, it is reported that there is a severe impairment of the differentiation of osteoblasts in *sfx* mice (20). Based on the several reports described above, ascorbic acid is evidently one of the important factors for maintaining the structure and function of bone, but the factors and mechanisms which are involved in this process are largely unknown. Therefore, we investigated the consequences of ascorbic acid insufficiency in *Gulo* (-/-) mice focusing on bone metabolism.

As shown in Figure 1, a decrease in body weight in ascorbic acid-insufficient *Gulo* (-/-) mice occurred at 4 weeks after ascorbic acid withdrawal. However, there was no evident weight change in ascorbic acid-insufficient *Gulo* (-/-) mice at 3 weeks after ascorbic acid withdrawal. This is in agreement with our previous report on the time- and organ-specific changes in the *in vivo* ascorbic acid concentration in *Gulo* (-/-) mice (15). Interestingly, there was a remarkable change in the trabecular bone volume near the growth plate in ascorbic acid-insufficient *Gulo* (-/-) mice at 3 weeks after ascorbic acid withdrawal, although there was no significant difference in weight. In accordance with our findings, similar results were found in ascorbic acid-deficient guinea pigs (19, 21). There was a definite change in bone volume without any evident physiological change observed in ascorbic acid-insufficient *Gulo* (-/-) mice at 3 weeks after ascorbic acid withdrawal, so it seems that ascorbic acid-deficiency exerts its initial effect on bone metabolism.

Alkaline phosphatase (ALP) and osteocalcin are representative markers of bone formation (22). Since both of these factors are increased by the activation of osteoblasts, the plasma levels of ALP and osteocalcin directly reflect the changes in bone formation *in vivo* (22, 23). As expected, we found a definite decrease of osteocalcin in the plasma of ascorbic acid-insufficient *Gulo* (-/-) mice upon ascorbic acid withdrawal for 3 and 4 weeks (Figure 3B), but the plasma concentration of alkaline phosphatase did not exhibit any significant changes in *Gulo* (-/-) mice at either of these timepoints after ascorbic acid withdrawal (Figure 3A). This may be due to the presence of a liver isoform of ALP in the circulation, since the liver is one of the major sources of blood ALP (24). Since ascorbic acid plays an important role in the production of various kinds of essential enzymes, especially in the liver, the increased ALP levels in the ascorbic acid-supplemented *Gulo* (-/-) mice appears to be the result of the continuous supplementation with ascorbic acid. Taken together, an abnormality of bone formation was developed in *Gulo* (-/-) mice upon ascorbic acid insufficiency. However, the underlying mechanisms related to the decrease in osteocalcin require further investigation.

Like the increase in the plasma ALP level that resulted from ascorbic acid supplementation, the tibia weight in ascorbic acid-sufficient *Gulo* (-/-) mice was higher than in the WT mice and ascorbic acid-insufficient *Gulo* (-/-) mice (Figure 4A). In particular, the relative ratio of the gross weight of the tibia against the final body weight was also significantly higher in ascorbic acid-sufficient *Gulo* (-/-) mice than in the WT (Figure 4B). Although this was not statistically significant, there was a trend to an increase in the plasma

osteocalcin level in the *Gulo* (-/-) mice by the supplementation of ascorbic acid. The amount of ascorbic acid used in this experiment was 3.3 g/L. Even though this is relatively higher than that spontaneously produced by mice, it suggests that sufficient amount or mega-dose uptake of ascorbic acid could enhance bone formation and effectively maintain bone health.

There have been reports that mega-doses of ascorbic acid have an enhancing effect on bone health in epidemiologic studies. According to a report by Hall et al., a positive association was found in postmenopausal estrogen/progestin trials between ascorbic acid intake and the BMD (bone mineral density) of the spine and hip (9). Interestingly, it is also reported that higher total ascorbic acid intake was associated with a reduction of femoral neck and trochanter BMD loss in men who had low calcium or low vitamin E intake (10). In addition, the femoral neck BMD in male nonsmokers is reportedly positively correlated with total ascorbic acid intake (10). However, there are other reports that did not find any positive correlation between ascorbic acid and bone health (25, 26). Therefore, further studies are required. Moreover, the evaluation of ascorbic acid levels in bone after either a sufficient amount or mega-dose is also needed.

Well organized trabecular bone was observed in WT mice and ascorbic acid-sufficient *Gulo* (-/-) mice (Figure 5 A, B). In addition, there was intact attachment of trabecular bone to the growth plate (Figure 5 E, F). The most striking findings in the ascorbic acid-insufficient *Gulo* (-/-) mice were the reduction of trabecular bone in the proximal metaphysis near the growth plate as well as just a small amount of trabecular bone attachment to the

growth plate (Figure 5 C, D, G, H). Since the area just distal of the growth plate is the most active site for new bone formation, it is thought that this is the reason that the reduction in the trabecular bone in the proximal metaphysis near the growth plate was more definitely observed than at any other site. Based on the previous reports of the trabecular bone reduction in ascorbic acid insufficient animal models (16, 21, 27), it is expected that other bony abnormalities, such as cortical bone thinning, growth plate reduction and malalignment would occur after a longer period of ascorbic acid withdrawal than was employed in this experiment.

In the present study, ascorbic acid-insufficient *Gulo(-/-)* mice exhibited low plasma osteocalcin levels and a definite reduction of trabecular bone in the proximal metaphysis near the growth plate. Moreover, all of these changes in bone metabolism and structure were not observed upon supplementation with a sufficient amount of ascorbic acid. Therefore, these findings suggest that the bone formation defect which occurs in cases of ascorbic acid-deficiency can be prevented with ascorbic acid supplementation. In addition, an enhancement of bone formation as well as the maintenance of bone health may be feasible with ascorbic acid supplementation. Further studies are needed.

REFERENCES

1. Fain O. Musculoskeletal manifestations of scurvy. Joint, bone, spine : revue du rhumatisme. 2005;72(2):124-8. Epub 2005/03/31.
2. Peterkofsky B. Ascorbate requirement for hydroxylation and secretion of procollagen: relationship to inhibition of collagen synthesis in scurvy. The American journal of clinical nutrition. 1991;54(6 Suppl):1135S-40S. Epub 1991/12/01.
3. Niyibizi C, Eyre DR. Structural characteristics of cross-linking sites in type V collagen of bone. Chain specificities and heterotypic links to type I collagen. European journal of biochemistry / FEBS. 1994;224(3):943-50. Epub 1994/09/15.
4. Cummine J, Armstrong L, Nade S. Osteogenesis after bone and bone marrow transplantation. Studies of cellular behaviour using combined myelo-osseous grafts in the subscorbutic guinea pig. Acta orthopaedica Scandinavica. 1983;54(2):235-41. Epub 1983/04/01.
5. Bourne G. The effect of graded doses of vitamin C upon the regeneration of bone in guinea-pigs on a scorbutic diet. The Journal of physiology. 1942;101(3):327-36. Epub 1942/11/30.
6. Leone J, Delhinger V, Maes D, Scheer C, Pennaforte JL, Eschard JP, et al. Rheumatic manifestations of scurvy. A report of two cases. Revue du rhumatisme (English ed). 1997;64(6):428-31. Epub 1997/06/01.
7. Shetty AK, Buckingham RB, Killian PJ, Girdany D, Meyerowitz R.

Hemarthrosis and femoral head destruction in an adult diet faddist with scurvy. *The Journal of rheumatology*. 1988;15(12):1878-80. Epub 1988/12/01.

8. Wapnick AA, Lynch SR, Seftel HC, Charlton RW, Bothwell TH, Jowsey J. The effect of siderosis and ascorbic acid depletion on bone metabolism, with special reference to osteoporosis in the Bantu. *The British journal of nutrition*. 1971;25(3):367-76. Epub 1971/05/01.

9. Hall SL, Greendale GA. The relation of dietary vitamin C intake to bone mineral density: results from the PEPI study. *Calcified tissue international*. 1998;63(3):183-9. Epub 1998/08/14.

10. Sahni S, Hannan MT, Gagnon D, Blumberg J, Cupples LA, Kiel DP, et al. High vitamin C intake is associated with lower 4-year bone loss in elderly men. *The Journal of nutrition*. 2008;138(10):1931-8. Epub 2008/09/23.

11. Ohta Y, Nishikimi M. Random nucleotide substitutions in primate nonfunctional gene for L-gulono-gamma-lactone oxidase, the missing enzyme in L-ascorbic acid biosynthesis. *Biochimica et biophysica acta*. 1999;1472(1-2):408-11. Epub 1999/11/26.

12. Nishikimi M, Fukuyama R, Minoshima S, Shimizu N, Yagi K. Cloning and chromosomal mapping of the human nonfunctional gene for L-gulono-gamma-lactone oxidase, the enzyme for L-ascorbic acid biosynthesis missing in man. *The Journal of biological chemistry*. 1994;269(18):13685-8. Epub 1994/05/06.

13. Nishikimi M, Kawai T, Yagi K. Guinea pigs possess a highly mutated gene for L-gulono-gamma-lactone oxidase, the key enzyme for L-ascorbic acid biosynthesis missing in this species. *The Journal of biological*

chemistry. 1992;267(30):21967-72. Epub 1992/10/25.

14. Maeda N, Hagihara H, Nakata Y, Hiller S, Wilder J, Reddick R. Aortic wall damage in mice unable to synthesize ascorbic acid. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(2):841-6. Epub 2000/01/19.

15. Kim H, Bae S, Yu Y, Kim Y, Kim H, Hwang Y, et al. The analysis of vitamin C concentration in organs of Gulo(-/-) mice upon vitamin C withdrawal. Immune netw. 2012;12:18-26.

16. Sakamoto Y, Takano Y. Morphological influence of ascorbic acid deficiency on endochondral ossification in osteogenic disorder Shionogi rat. The Anatomical record. 2002;268(2):93-104. Epub 2002/09/11.

17. Hasegawa T, Li M, Hara K, Sasaki M, Tabata C, de Freitas PH, et al. Morphological assessment of bone mineralization in tibial metaphyses of ascorbic acid-deficient ODS rats. Biomedical research (Tokyo, Japan). 2011;32(4):259-69. Epub 2011/09/01.

18. Tsuchiya H, Bates CJ. Ascorbic acid deficiency in guinea pigs: contrasting effects of tissue ascorbic acid depletion and of associated inanition on status indices related to collagen and vitamin D. The British journal of nutrition. 1994;72(5):745-52. Epub 1994/11/01.

19. Mahmoodian F, Gosiewska A, Peterkofsky B. Regulation and properties of bone alkaline phosphatase during vitamin C deficiency in guinea pigs. Archives of biochemistry and biophysics. 1996;336(1):86-96. Epub 1996/12/01.

20. Mohan S, Kapoor A, Singgih A, Zhang Z, Taylor T, Yu H, et al.

Spontaneous fractures in the mouse mutant sfx are caused by deletion of the gulonolactone oxidase gene, causing vitamin C deficiency. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*. 2005;20(9):1597-610. Epub 2005/08/02.

21. Kipp DE, McElvain M, Kimmel DB, Akhter MP, Robinson RG, Lukert BP. Scurvy results in decreased collagen synthesis and bone density in the guinea pig animal model. *Bone*. 1996;18(3):281-8. Epub 1996/03/01.

22. Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: understanding their value in clinical trials and clinical practice. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*. 2009;20(6):843-51. Epub 2009/02/05.

23. Kim D. Biochemical Markers of Bone Turnover. *The Korean Journal of Nuclear Medicine*. 1999;33(4):341-51.

24. Green S, Anstiss CL, Fishman WH. Automated differential isoenzyme analysis. II. The fractionation of serum alkaline phosphatases into "liver", "intestinal" and "other" components. *Enzymologia*. 1971;41(1):9-26. Epub 1971/07/31.

25. Wolf RL, Cauley JA, Pettinger M, Jackson R, Lacroix A, Leboff MS, et al. Lack of a relation between vitamin and mineral antioxidants and bone mineral density: results from the Women's Health Initiative. *The American journal of clinical nutrition*. 2005;82(3):581-8. Epub 2005/09/13.

26. Leveille SG, LaCroix AZ, Koepsell TD, Beresford SA, Van Belle G, Buchner DM. Dietary vitamin C and bone mineral density in postmenopausal

women in Washington State, USA. *Journal of epidemiology and community health*. 1997;51(5):479-85. Epub 1998/01/13.

27. Tsunenari T, Fukase M, Fujita T. Bone histomorphometric analysis for the cause of osteopenia in vitamin C-deficient rat (ODS rat). *Calcified tissue international*. 1991;48(1):18-27. Epub 1991/01/01.

국문 초록

L-gulonono- γ -lactone 산화효소(Gulo)는 포도당으로부터 아스코르빈산을 합성하는데 있어서 필수적인 효소이다. 사람과 몇몇 유인원에서는 *gulo* 유전자의 변이가 있는데, 그로 인해 이들은 아스코르빈산을 체내에서 합성하지 못한다. *Gulo* (-/-) 생쥐는 사람과 같이 *gulo* 유전자의 발현에 결핍이 있기 때문에, 아스코르빈산을 결핍시킨 상태에서 키울 경우에 사람 괴혈병에 대해 연구하는데 유용한 동물 모델로 이용된다. 본 연구팀은 이전 연구에서 다발성 늑골연골 접합부 골절과 같은 뼈의 이상이 아스코르빈산을 결핍시킨 *Gulo* (-/-) 생쥐에서 발생하는 것을 관찰하였다. 이를 바탕으로 본 연구에서는 아스코르빈산의 결핍이 *Gulo* (-/-) 생쥐의 뼈 대사에 미치는 영향 및 관련 인자에 대해 분석하였다. 아스코르빈산의 공급을 중단하고 4 주 짜가 되자 아스코르빈산을 결핍시킨 *Gulo* (-/-) 생쥐에서 분명한 체중의 감소가 관찰되었다. 흥미롭게도 뼈의 대사를 조절하고 골모세포에 의해서만 분비되는 오스테오칼신의 혈장내 농도가 아스코르빈산의 공급을 중단한지 3 주 짜에 *Gulo* (-/-) 생쥐에서 급격히 감소하였고, 4 주 짜에는 오스테오칼신이 검출되지 않았다. 경골의 무게는 아스코르빈산을

충분히 공급하여준 *Gulo* (-/-) 생쥐에서 다른 3 군보다 더 나갔다. 아스코르빈산을 결핍시킨 후 3 주와 4 주 차의 *Gulo* (-/-) 생쥐에서는 성장판 근처에서 해면골의 양이 감소되어 있었고 해면골과 성장판과의 부착이 감소되어 있었다. 이상의 소견은 아스코르빈산의 결핍은 정상적인 뼈의 생성에 심각한 장애를 일으키며, 이는 오스테오칼신 농도의 감소와 밀접하게 연관되어있음을 시사한다.

주요단어: 아스코르빈산, 비타민 C, *Gulo*, 오스테오칼신, 뼈 생성

학번: 2007-23330